Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efecto de la Dieta Mediterránea Modificada Basada en Baja Histamina en la Esclerosis Múltiple (HistaMed-MS)

14 de noviembre de 2026 actualizado por: Murat Açık, Firat University

Un Ensayo Controlado Aleatorizado de una Dieta Mediterránea Modificada Baja en Histamina en la Esclerosis Múltiple: El Efecto de las Intervenciones Dietéticas sobre los Hallazgos Clínicos, la Histamina Plasmática y el Estrés Oxidativo

This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS). The study will compare three groups: a low-histamine modified Mediterranean diet, a traditional Mediterranean diet, and a control group without dietary intervention. The main outcomes include clinical measures such as disability status, fatigue, and quality of life, as well as blood markers including plasma histamine, diamine oxidase concentration, total antioxidant capacity, and oxidative stress indicators. The goal is to determine whether reducing dietary histamine within a Mediterranean diet pattern provides additional benefits beyond a traditional Mediterranean diet in improving symptoms and biological markers related to inflammation and oxidative stress in RRMS.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Current immunomodulatory treatments have important side effects and do not fully address symptoms or quality of life, highlighting the need for complementary strategies such as targeted dietary interventions. The Mediterranean diet is one of the most promising patterns because of its anti-inflammatory and antioxidant properties and has been associated with reduced fatigue, improved quality of life, and potential benefits on disability in people with MS. However, some components of the traditional Mediterranean diet, such as certain fish, aged cheeses, fermented products, tomatoes, and citrus fruits, are relatively high in histamine. Histamine is a biogenic amine that may influence neuroinflammation and blood-brain barrier permeability, and diets that lower histamine intake have shown benefits in conditions like migraine and gastrointestinal dysfunction, which are common in MS. This study was designed to explore whether a low histamine-based modified Mediterranean diet can optimize the benefits of the Mediterranean pattern in relapsing-remitting MS (RRMS).

The trial is a three-arm, parallel-group, randomized controlled clinical study in adults with RRMS. Participants are randomly assigned to one of three groups: (1) a low histamine-based modified Mediterranean diet, which maintains the core principles of the Mediterranean pattern while restricting foods known to be high in histamine or to promote histamine release; (2) a traditional Mediterranean diet without specific histamine-related restrictions; or (3) a control group that does not receive a structured dietary intervention. The intervention focuses on high intake of fresh vegetables and fruits, legumes, whole grains, olive oil, and appropriate fish options, while the modified diet group additionally limits aged cheeses, processed meats, fermented foods, vinegar, fish and seafood, and selected vegetables and fruits that are high in histamine. This design allows direct comparison of no diet intervention, a well-established Mediterranean pattern, and a targeted low-histamine modification of that pattern.

Clinical outcomes include disability status assessed by the Expanded Disability Status Scale (EDSS), fatigue measured with the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), and health-related quality of life evaluated with the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. To investigate potential mechanisms, blood biomarkers are measured, including serum total antioxidant capacity, oxidative stress markers (for example malondialdehyde), plasma histamine levels, and plasma concentration of diamine oxidase (DAO), an enzyme that metabolizes histamine. The primary hypotheses are that both Mediterranean diet interventions will improve fatigue, quality of life, and oxidative stress parameters compared with the control group, and that the low histamine-based modified Mediterranean diet will provide the greatest benefits, particularly in reducing plasma histamine, increasing DAO concentration, and alleviating fatigue and disability scores in RRMS. If confirmed, the findings could support a more targeted dietary approach as a complementary medical nutrition therapy for MS and provide a basis for future interventional studies on histamine metabolism, oxidative stress, and diet in this population.

Tipo de estudio

Intervencionista

Inscripción (Actual)

57

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Elâzığ
      • Elâzığ, Elâzığ, Turquía (Türkiye), 23119
        • Firat University Hospital, Neurology Clinic

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

19 años a 64 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 19 to 64 years.
  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to 2017 McDonald criteria.
  • EDSS score < 4.5.
  • On stable immunomodulatory treatment for at least 6 months.
  • Body mass index (BMI) 18.5-29.9 kg/m².

Exclusion Criteria:

  • Relapse and/or corticosteroid treatment within the last 1 month.
  • Clinically significant metabolic, progressive, or malignant disease.
  • Use of at least 1 g/day fish oil supplementation.
  • Insulin-dependent diabetes mellitus.
  • Participation in another interventional study.
  • Weight loss or gain ≥ 5% in the last 6 months.
  • Following a weight-loss diet in the last 2 months.
  • Use of oral anticoagulant therapy.
  • Presence of eating disorders, alcohol or substance dependence.
  • Pregnancy or breastfeeding.
  • Inability to comply with dietary intervention according to weekly follow-up assessments.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Low Histamine-Based Modified Mediterranean Diet

Participants receive a low histamine-based modified Mediterranean diet with restriction of high-histamine and histamine-releasing foods while preserving core Mediterranean diet principles.

Structured dietary program based on the Mediterranean diet with restriction of high-histamine and histamine-releasing foods (e.g., aged cheeses, processed meats, fish and seafood, fermented products, vinegar, some fruits and vegetables); fish is replaced with poultry.

Comparador activo: Traditional Mediterranean Diet

Participants receive a traditional Mediterranean diet without specific histamine-related restrictions.

Structured dietary program following a traditional Mediterranean diet rich in vegetables, fruits, whole grains, legumes, olive oil, and fish, without specific histamine-related restrictions.

Sin intervención: Control (Usual Diet)

Participants continue their usual diet and do not receive a structured dietary intervention.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in neurological fatigue (Neurological Fatigue Index for Multiple Sclerosis [NFI-MS] subscale scores; ranges: physical fatigue 0-24, cognitive fatigue 0-12, diurnal sleep 0-18, nocturnal sleep 0-15; higher scores indicate greater fatigue)
Periodo de tiempo: Baseline, week 6 and week 12

Fatigue will be assessed using the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), a 23-item self-reported questionnaire with four subscales: physical fatigue (8 items), cognitive fatigue (4 items), relief by diurnal sleep or rest (6 items), and abnormal nocturnal sleep and sleepiness (5 items). Items are rated from 0 to 3, each subscale is scored separately (no total score is calculated), and higher scores indicate greater fatigue. The outcome is the change in each subscale score from baseline to week 12 across the three study groups.

Baseline, week 6 and week 12
Change in plasma histamine concentration
Periodo de tiempo: From baseline to 12 weeks

Plasma histamine will be measured in fasting EDTA plasma by competitive ELISA. The outcome is the change in plasma histamine concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks
Change in plasma diamine oxidase (DAO) concentration
Periodo de tiempo: From baseline to 12 weeks

Plasma diamine oxidase (DAO), a key enzyme of histamine metabolism, will be measured in fasting EDTA plasma by sandwich ELISA. The outcome is the change in plasma DAO concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in disability status (Expanded Disability Status Scale [EDSS]; scale range: 0-10; higher scores indicate greater disability)
Periodo de tiempo: From baseline to 12 weeks

Disability will be assessed using the Expanded Disability Status Scale (EDSS). The outcome is the change in EDSS score from baseline to the end of the intervention.

From baseline to 12 weeks
Change in health-related quality of life (Multiple Sclerosis Quality of Life-54 [MSQOL-54]; scale range: 0-100 for subscale and composite scores; higher scores indicate better health-related quality of life)
Periodo de tiempo: From baseline to 12 weeks

Health-related quality of life will be assessed using the MSQOL-54 questionnaire. The outcome is the change in MSQOL-54 scores from baseline to the end of the intervention.

From baseline to 12 weeks
Change in serum total antioxidant capacity
Periodo de tiempo: From baseline to 12 weeks

Serum total antioxidant capacity will be measured to evaluate antioxidant status. The outcome is the change in serum total antioxidant capacity between baseline and the end of the intervention.

From baseline to 12 weeks
Change in oxidative stress markers (e.g., malondialdehyde)
Periodo de tiempo: From baseline to 12 weeks

Oxidative stress will be assessed using markers such as malondialdehyde (MDA). The outcome is the change in oxidative stress markers between baseline and the end of the intervention.

From baseline to 12 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Murat Gönen, Prof. Dr., Firat University Faculty of Medicine

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

15 de junio de 2024

Finalización primaria (Actual)

10 de marzo de 2025

Finalización del estudio (Actual)

10 de junio de 2025

Fechas de registro del estudio

Enviado por primera vez

22 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de marzo de 2026

Publicado por primera vez (Actual)

30 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2023/03-26
  • 223S505 (Otro identificador: The Scientific and Technological Research Council of Turkey (TÜBİTAK))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

De-identified individual participant data underlying the results reported in the publication will be shared, together with the data dictionary.

Marco de tiempo para compartir IPD

Beginning after publication of the main results.

Criterios de acceso compartido de IPD

Available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

Tipo de información de apoyo para compartir IPD

  • CÓDIGO_ANALÍTICO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .